Acetamiprid Accumulates in Different Amounts in Murine Brain Regions

• Main Authors: Hayato Terayama, Hitoshi Endo, Hideo Tsukamoto, Koichi Matsumoto, Mai Umezu, Teruhisa Kanazawa, Masatoshi Ito, Tadayuki Sato, Munekazu Naito, Satoshi Kawakami, Yasuhiro Fujino, Masayuki Tatemichi, Kou Sakabe
• Format: Article
• Language: English
• Published: MDPI AG 2016-09-01
• Series: International Journal of Environmental Research and Public Health
• Subjects: acetamiprid; mouse; brain; concentration; neonicotinoid
• Online Access: http://www.mdpi.com/1660-4601/13/10/937

Neonicotinoids such as acetamiprid (ACE) belong to a new and widely used single class of pesticides. Neonicotinoids mimic the chemical structure of nicotine and share agonist activity with the nicotine acetylcholine receptor (nAchR). Neonicotinoids are widely considered to be safe in humans; however, they have recently been implicated in a number of human health disorders. A wide range of musculoskeletal and neuromuscular disorders associated with high doses of neonicotinoids administered to animals have also been reported. Consequently, we used a mouse model to investigate the response of the central nervous system to ACE treatment. Our results show that exposure to ACE-containing water for three or seven days (decuple and centuple of no observable adverse effect level (NOAEL)/day) caused a decrease in body weight in 10-week old A/JJmsSlc (A/J) mice. However, the treatments did not affect brain histology or expression of CD34. ACE concentrations were significantly higher in the midbrain of ACE-treated mice than that of the normal and vehicle groups. Expression levels of α7, α4, and β2 nAChRs were found to be low in the olfactory bulb and midbrain of normal mice. Furthermore, in the experimental group (centuple ACE-containing water for seven days), β2 nAChR expression decreased in many brain regions. Information regarding the amount of accumulated ACE and expression levels of the acetylcholine receptor in each region of the brain is important for understanding any clinical symptoms that may be associated with ACE exposure.